Kyiv-based private joint-stock company Indar, the only Ukrainian company with a full cycle of insulin production, has won a tender of the Health Ministry of Ukraine on supply of 6.798 million pills of anti-tuberculosis medicine – Cycloserine, the company has told Interfax-Ukraine.

The company said that Indar will supply the medicine at UAH 6 per pill.

In 2012, when Indar did not take part in the state procurement, the ministry bought Cycloserine at UAH 8.65 per pill.

"The offer of Indar allowed saving over UAH 10.8 million for the Health Ministry of Ukraine on the purchases of Cycloserine," the company said.

Indar Board Chairman Liubov Vyshnevska told Interfax-Ukraine that Cycloserine, which will be delivered to the ministry, is a medicine made by a large international company, which is being packed at the facilities of Indar.

Indar did not disclose the name of the international company under the agreement on confidentiality.

As reported, Indar earlier reported that it plans to start packaging anti-AIDS and tuberculosis medicine made by an international producer at its facilities.

Indar in 2012 cut its net profit by 12.6 times compared with 2011, to UAH 267,000, its net revenue dropped by 15.7%, to UAH 108.082 million, and gross profit grew by 29%, to UAH 45.527 million.

In 2012, the state fully reinstated control over the enterprise, which was lost in 2008 when the state stake of 70.7% belonged to Ukrmedprom was old to Storke Holdings Limited (Belize). As of late Q4, 2012, a 70.7% stake in Indar belonged to Ukrmedprom and a 21.1% stake to private joint-stock company AUSD.

Indar was created under a resolution of the Cabinet of Ministers in 1997 on the basis of Kyiv meat processing plant.